百奥赛图（股票代码：02315.HK）是一家创新技术驱动新药研发的国际性生物技术公司，致力于成为全球新药发源地。基于底层基因编辑技术，百奥赛图自主研发了RenMice平台，用于全人治疗性单克隆抗体、双/多特异性抗体、双抗ADC、纳米抗体和类TCR抗体的发现。百奥赛图正在对1000多个潜在可成药的靶点进行规模化药物开发（“千鼠万抗TM”计划），并已建立起超100万条全人抗体序列库，用于全球合作。公司子品牌BioMice®提供几千种包括靶点人源化小鼠在内的基因编辑动物和细胞模型，同时为全球客户提供临床前药理药效和基因编辑服务。

Fully Human Antibody LibraryPreclinical PCC and Clinical AssetsAntibody Assets Licensing & Co-DevelopmentBiocytogen’s fully human antibody library is comprised of 400K+ sequences targeting 900+ antigens, applicable to multiple therapeutic areas. These antibodies were generated using proprietary RenMice® strains, each engineered to lack a certain drug target gene. This fully human, hyperimmune, target-specific (HiTS) platform increases the likelihood that our antibodies have desirable charac

Biocytogen provides a number of off-the-shelf genetically modified animal models for basic and preclinical research. Our comprehensive catalog includes:Humanized immune checkpoint mouse models (single, double, or triple targets in one model)Humanized cytokine & GPCR modelsImmunodeficient rodent modelsEngineered cell lines including humanized cell lines The models are ready to use for your research and applications. Contact Us to speak with our model experts.

Biocytogen provides comprehensive, one-stop solutions for next-generation drug development, supporting the global biomedical community from target identification to IND application. Leveraging cutting-edge gene-editing technology and advanced pharmacological capabilities, Biocytogen offers a diverse portfolio of oncology-focused products and services.In Vivo Models for Oncology ResearchSyngeneic modelsXenograft modelsHuman immune system reconstitution modelsOrthotopic modelsSolutions fo

Biocytogen has developed a comprehensive portfolio of humanized mice and disease models to support research in autoimmune and inflammatory disorders—including asthma, atopic dermatitis (AD), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pulmonary fibrosis, and more.By enabling more predictive in vivo studies through humanized targets and disease-relevant models, our platforms help bridge the translational gap between therapeutic discove

Metabolic mechanisms are central to the onset and progression of chronic illnesses, yet their complexity poses persistent challenges in therapeutic development. To address this, Biocytogen has established and continues to expand a comprehensive portfolio of drug-targeted humanized mice and disease models for glucose and lipid metabolism disorders. These advanced preclinical models are designed to accelerate drug discovery and development for a range of metabolic disorders, including diabetes, ob

Biocytogen has developed advanced humanized mouse models and offers comprehensive pathology services and preclinical drug testing—along with capabilities in animal behavioral assessments—all specifically designed to advance research into critical neurological conditions such as BBB crossing, Alzheimer’s disease, autism spectrum disorder, amyotrophic lateral sclerosis, Parkinson’s disease, and more. Download our brochure to learn more!